ATE464564T1 - Screening-verfahren - Google Patents

Screening-verfahren

Info

Publication number
ATE464564T1
ATE464564T1 AT05776830T AT05776830T ATE464564T1 AT E464564 T1 ATE464564 T1 AT E464564T1 AT 05776830 T AT05776830 T AT 05776830T AT 05776830 T AT05776830 T AT 05776830T AT E464564 T1 ATE464564 T1 AT E464564T1
Authority
AT
Austria
Prior art keywords
salt
screening
protein
amino acid
acid sequence
Prior art date
Application number
AT05776830T
Other languages
English (en)
Inventor
Yasuaki Ito
Kazunori Nishi
Shoichi Ohkubo
Masataka Harada
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE464564T1 publication Critical patent/ATE464564T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
AT05776830T 2004-08-30 2005-08-29 Screening-verfahren ATE464564T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004250786 2004-08-30
PCT/JP2005/016169 WO2006025551A1 (ja) 2004-08-30 2005-08-29 スクリーニング方法

Publications (1)

Publication Number Publication Date
ATE464564T1 true ATE464564T1 (de) 2010-04-15

Family

ID=36000195

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05776830T ATE464564T1 (de) 2004-08-30 2005-08-29 Screening-verfahren

Country Status (6)

Country Link
US (1) US7892755B2 (de)
EP (1) EP1788390B1 (de)
JP (1) JP4772684B2 (de)
AT (1) ATE464564T1 (de)
DE (1) DE602005020646D1 (de)
WO (1) WO2006025551A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120022116A1 (en) * 2010-07-20 2012-01-26 Huayun Deng Compositions and methods for the treatment of pathological condition(s) related to gpr35 and/or gpr35-herg complex
CN109929805A (zh) * 2017-12-15 2019-06-25 中国科学院大连化学物理研究所 鼠源gpr35高通量筛选模型的构建方法及应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2832726B2 (ja) * 1989-08-03 1998-12-09 日本ケミファ株式会社 消化管運動抑制用医薬組成物
CA2219605C (en) 1996-10-31 2002-02-05 Deepa Ashok Khambe Method of stimulating gastrointestinal motility with ellagic acid
US20020168720A1 (en) * 1997-02-06 2002-11-14 Takeda Chemical Industries Ltd. G protein coupled receptor proteins, their production and use
US7119190B2 (en) * 1997-04-14 2006-10-10 Arena Pharmaceuticals, Inc. Endogenous and non-endogenous versions of human G protein-coupled receptors
DE19728326A1 (de) 1997-06-27 1999-01-07 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
CA2316283A1 (en) * 1997-12-26 1999-07-08 Banyu Pharmaceutical Co., Ltd. Novel guanosine triphosphate (gtp) binding protein-coupled receptor protein
JP2002517222A (ja) 1998-06-11 2002-06-18 スミスクライン ビーチャム コーポレーション Ｇｐｒ３５ａ受容体
AU2398501A (en) * 1999-12-20 2001-07-03 Banyu Pharmaceutical Co., Ltd. Novel guanosine triphosphate-binding protein-coupled receptor protein, bg26
WO2002009734A1 (fr) * 2000-08-01 2002-02-07 Oryza Oil & Fat Chemical Co.,Ltd. Inhibiteurs d'absorption de sucre et leur procede de production
WO2002068600A2 (en) * 2001-02-26 2002-09-06 Arena Pharmaceuticals, Inc. Endogenous and non-endogenous versions of human g protein-coupled receptors
US7102000B2 (en) * 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
CA2498264A1 (en) * 2002-09-09 2004-05-13 Nura, Inc. G protein coupled receptors and uses thereof
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1447413A3 (de) * 2003-02-14 2006-01-04 Research Association for Biotechnology Vollständige humane cDNA
US20070048740A1 (en) 2003-02-14 2007-03-01 Research Association For Biotechnology Full-length cDNA
EP1522858A1 (de) * 2003-10-10 2005-04-13 Jean-Christophe Roegel Methoden für Selektion von Verbindungen unter Verwendung von Antikörpern mit Aktivität als Agonist, Antagonist oder allosterischen Modulatoren
WO2005059546A2 (en) 2003-12-12 2005-06-30 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 35 (gpr35)

Also Published As

Publication number Publication date
JP4772684B2 (ja) 2011-09-14
US20080103215A1 (en) 2008-05-01
US7892755B2 (en) 2011-02-22
WO2006025551A1 (ja) 2006-03-09
EP1788390B1 (de) 2010-04-14
DE602005020646D1 (de) 2010-05-27
EP1788390A4 (de) 2008-02-13
EP1788390A1 (de) 2007-05-23
JPWO2006025551A1 (ja) 2008-05-08

Similar Documents

Publication Publication Date Title
WO2005111066A3 (en) Polypeptides from non-typeable haemophilus influenzae
WO2004078777A3 (en) Dipeptidyl-peptidase protected proteins
WO2006087550A3 (en) Amyloid-binding peptides, analogues and uses thereof
EA200800536A1 (ru) Тканезащитные пептиды и их применения
DK1961811T3 (da) Cytokinligand til behandling af asthma og luftvejs-hyper-responsivitet
PT1171465E (pt) Analogos de petido inibidor gastrico e sua utilizacao para o tratamento de diabetes
WO2009004315A8 (en) Isolated peptides and uses thereof
EA200700136A1 (ru) Анти-cd154-антитела
WO2008074840A3 (en) Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
TW200616657A (en) Therapeutic peptides and method
BRPI0506771A (pt) anticorpo, e, composição farmacêutica
DK2020604T3 (da) Ligand for den G-proteinkoblede receptor FPRL2
WO2005051998A3 (en) Antibodies binding to a c-terminal fragment of apolipoprotein e
BR0306715A (pt) Métodos para diagnóstico e tratamento de tumores
ATE464564T1 (de) Screening-verfahren
ATE405827T1 (de) Screening-verfahren
WO2004069860A3 (en) Isg15-conjugated proteins
ATE485831T1 (de) Behandlung von neurodegeneration
EP1760087A4 (de) Neuer proteinkomplex und anwendungen davon
CY1109904T1 (el) Προαγωγεας της il-18bp, η παρασκευη και χρηση του
EP1584925A4 (de) Neues screening-verfahren
TW200517125A (en) Pharmaceutical composition for treatment of solid cancers
DE60321443D1 (de) Screening-verfahren für eine prophylaktische und therapeutische Substanz für eine Nierenerkrankung
WO2007020405A3 (en) Integrin i-domain binding peptides
EP1455186A4 (de) Screening-verfahren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties